ZIKA Virus Risk Assessment
Customize your policy alerts
Sign up for avalon_healthcare_solutions Policy AHS - G2133 - ZIKA Virus Risk Assessment alerts
Get alerted when Policy AHS - G2133 - ZIKA Virus Risk Assessment changes without checking for updates manually.
Monitor payer policy activity
Defines coverage criteria for Zika virus diagnostic testing (NAAT and IgM) in infants, pregnant and non-pregnant individuals, and lists indications, limitations, and sample types that meet or do not meet coverage for Avalon Healthcare Solutions members.
Policy archived and coverage criteria moved into G2158; Committee Approval 08/15/2023.
FDA approvals for cobas Zika (2017) and Procleix Zika Virus Assay (2018) with performance characteristics are documented.
Added coverage for NAAT testing of maternal serum and urine in specific pregnant populations and clarified limits for preconception and non-pregnant testing.
Coverage Criteria for Zika Virus Testing
inv-01: Covered Indications
Covered when ALL of the following are met as specified below:
Samples: serum, urine, CSF; maternal laboratory evidence considered acceptable.
Maternal NAAT specimen types: serum and urine.
IgM testing limited to cases with abnormal fetal ultrasound.
Specimens: amniocentesis fluid, placental and fetal tissues.
inv-03: Covered Indications
Coverage aligned with cited guideline-based indications — testing recommended in the following distinct clinical groups
Molecular testing recommended early after symptom onset per guideline sources; see CDC recommendations.
If maternal ultrasound suggests Zika infection, perform maternal NAAT and IgM and maternal urine NAAT; consider amniocentesis NAAT and placental/fetal tissue testing; confirmatory PRNT is recommended for positive/equivocal IgM results.
Testing modalities include NAAT/RT-PCR and IgM with PRNT confirmation as needed.
Donor screening uses FDA-authorized assays with described sensitivity/specificity; clinical-use LDTs are regulated under CLIA.
inv-04: Migrated coverage criteria (see G2158)
Coverage criteria updated and relocated
Operationally the policy content was archived and its coverage criteria transferred to G2158.
inv-02: Not Covered / Exclusions
These are explicit exclusions in the policy.
The policy explicitly lists scenarios that do not meet coverage. Preconception screening using Zika virus urine or serum NAAT and Zika virus serum IgM testing does not meet coverage criteria. Likewise, Zika testing in non-pregnant individuals presenting ≥14 days after symptom onset (urine or serum NAAT and serum IgM) does not meet coverage criteria. The policy further states that testing of sample types or assays not enumerated (outside serum, urine, CSF, amniocentesis fluid, placental and fetal tissues) does not meet coverage criteria due to insufficient published evidence.
Routine testing of asymptomatic persons is not recommended by major public health bodies and is therefore excluded from routine coverage. The CDC and CATMAT recommend against routine testing of asymptomatic nonpregnant individuals and caution that routine serologic screening of asymptomatic pregnant women has poor positive predictive value and may produce false positives. Public Health England's algorithms similarly do not provide a testing route for individuals without symptoms; routine testing of asymptomatic travelers or persons without ongoing exposure is not recommended.
For preconception screening the policy is explicit: Zika virus urine and serum NAAT testing and Zika virus serum IgM testing do not meet coverage criteria. This exclusion was retained and clarified in the revision history and subsequently migrated into the superseding policy (G2158).
The policy expands on exclusions for preconception and other non-pregnant testing: testing for preconception purposes and testing of non-pregnant individuals ≥14 days after symptom onset are categorized as not meeting coverage. These stances align with guideline recommendations that discourage routine serologic screening in asymptomatic people and limit molecular testing to specific clinical windows and populations.
Asymptomatic travelers and individuals without ongoing exposure are generally not appropriate candidates for routine Zika testing under this policy. CDC guidance notes that NAAT may be considered up to 12 weeks post-travel for asymptomatic pregnant persons returning from risk areas outside U.S. territories, but routine testing of asymptomatic travelers or those without ongoing exposure is not routinely recommended and may be denied.
The policy states that in non-pregnant individuals presenting ≥14 days after symptom onset, Zika virus urine and serum NAAT testing and Zika virus serum IgM testing do not meet coverage criteria. This limitation reflects the reduced diagnostic yield of NAAT after the acute window and the limited utility of IgM testing in later presentations; the revision history documents this explicit exclusion and its migration into G2158.
Coding
Provider Actions and Authorization
Prior authorization required when testing falls under covered indications per plan
Coverage is specific to the listed indications and specimen types; prior authorization may be required per plan benefits and should reference the documented clinical indication and specimen type when testing meets coverage criteria.
- Apply for prior authorization when requesting NAAT or IgM testing that falls under the policy's covered indications (infant, maternal, or fetal/placental scenarios).
- Reference the patient’s clinical findings, exposure history, timing of symptoms/travel, and specimen type on the authorization request.
Prior authorization likely for non-recommended testing
Testing requests for populations and indications that the policy and guideline bodies do not recommend (e.g., asymptomatic nonpregnant persons, routine serology in asymptomatic pregnant women, or preconception screening) will draw prior authorization scrutiny and may be denied.
- Be prepared to justify medical necessity for testing outside recommended groups; expect denials for routine asymptomatic screening.
- Serum IgM testing in nonrecommended contexts is especially likely to require additional rationale or confirmatory testing.
Prior authorization defined in G2158
Operationally this policy was archived and its coverage criteria were moved into policy G2158; any prior authorization requirements (and the process for obtaining them) are defined in G2158.
No step therapy requirements specified
No step therapy requirements apply for Zika virus diagnostic testing in this policy.
- There are no sequential treatment or testing prerequisites listed — proceed with testing authorization based on coverage criteria rather than step therapy algorithms.
Follow-up serology and PRNT confirmation after negative NAAT or positive/equivocal IgM
If RNA NAAT (RNA NAT/NAAT) is negative, follow-up with serum IgM testing per CDC guidance; positive or equivocal IgM results should be confirmed by PRNT before concluding diagnosis.
- A negative NAAT does not exclude infection and should prompt IgM serology when clinically indicated.
- Positive/equivocal IgM requires confirmatory PRNT (CDC-qualified labs) to distinguish Zika from cross-reacting flavivirus antibodies.
Migrated policy note — consult G2158
(Migrated/placeholder) See current policy G2158 for detailed operational requirements and authorization pathways now that this policy is archived.
- Use G2158 as the authoritative source for current coverage and authorization procedures.
Document clinical findings and exposure/timing to support testing
Document clinical findings, maternal laboratory/imaging details, exposure history, timing of symptom onset or travel relative to testing, and specimen type to support coverage determinations and any prior authorization.
- Include prenatal ultrasound findings (if present), congenital Zika syndrome signs in infants, and maternal exposure details (travel/sexual/blood exposure).
- Record timing of symptoms or travel relative to specimen collection and specify specimen type (serum, urine, CSF, amniotic fluid, placental/fetal tissue).
Maternal testing when fetal ultrasound suggests Zika infection
When prenatal ultrasound suggests possible fetal Zika infection, perform NAAT and IgM on maternal serum and NAAT on maternal urine; if positive or discordant, perform confirmatory PRNTs and document any amniocentesis testing if performed.
- Order maternal serum NAAT and IgM plus maternal urine NAAT when fetal ultrasound is consistent with congenital Zika infection.
- If amniocentesis is performed as part of care, Zika NAAT of amniotic fluid may be done and results should be interpreted in context of test limitations; confirmatory PRNT is required for positive/equivocal IgM.
Document assay and specimen (assay-specific intended use)
When ordering or reporting tests, document the specific assay used and the specimen type consistent with intended use (for example, FDA-approved donor assays such as cobas Zika or Procleix are for plasma/serum donor screening and are not intended as clinical diagnostic aids).
Do not use testing for preconception screening or non-pregnant ≥14 days post-symptom onset
Zika virus urine and serum NAAT testing and Zika virus serum IgM testing for preconception screening, and testing of non-pregnant individuals presenting ≥14 days after symptom onset, do not meet coverage criteria and may be denied.
- Do not submit claims for preconception screening NAAT or IgM testing expecting coverage under this policy; seek authorization per G2158 if applicable.
- Testing non-pregnant individuals ≥14 days after symptom onset is explicitly excluded from coverage.
Expect denials for asymptomatic testing outside guidance
Testing algorithms and guidance generally do not provide routes for testing in the absence of symptoms; expect denials for asymptomatic testing outside guideline-recommended scenarios (e.g., routine asymptomatic screening of travelers or pregnant women without ultrasound abnormalities).
- For asymptomatic individuals without ongoing exposure, testing is generally not medically necessary per CDC, PHE, and other bodies.
- Provide clear clinical justification if seeking testing for an asymptomatic patient; otherwise prior authorization or claims may be denied.
Policy archived — seek authorization and submit claims under G2158
This policy was archived and coverage criteria were transferred to policy G2158; claims or prior authorization requests that reference this archived document risk denial if not aligned with the current G2158 criteria and authorization processes.
- Consult policy G2158 for the current coverage criteria, prior authorization requirements, and claim submission expectations for Zika testing.
- Claims referencing this archived policy should be updated to reflect G2158 or may be denied.
Background
Zika virus is a flavivirus primarily transmitted by infected Aedes mosquitoes and also by sexual contact or blood exposure; infection is often asymptomatic or causes a mild febrile illness with rash, arthralgia, and conjunctivitis. Definitive laboratory diagnosis relies on nucleic acid amplification testing (NAAT/RT-PCR) to detect viral RNA in serum, urine or other tissues, while serologic IgM testing can indicate recent infection but is limited by cross-reactivity with other flaviviruses and prolonged IgM persistence. These clinical and diagnostic characteristics underpin the policy’s focused coverage for pregnant persons, infants with compatible findings, and select diagnostic specimen types.
Definitions and Test Modalities
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.